Q-omics provides the consensus-scored MLLT10 profile across patient tissues and cancer cell-line models. MLLT10 expression is associated with patient survival in 26 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, MLLT10 is differentially expressed in 9, with the highest sampling consensus in COAD. Additionally, MLLT10 RNA expression shows 20,624 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight KIRC, COAD, and ACC as cancer lineages where MLLT10 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MLLT10 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MLLT10 survival associations across molecular data types. MLLT10 RNA expression shows survival associations in the most cancer types (26), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MLLT10 RNA expression–survival associations across cancer types. High MLLT10 expression shows unfavorable associations in ACC, BLCA, LIHC and LGG, but favorable associations in KIRC and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for MLLT10 RNA expression.
This table summarizes MLLT10 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 6. The strongest signals are observed in COAD for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for MLLT10. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MLLT10 shows lower tumor expression in KICH, UCEC and THCA and higher tumor expression in COAD, LIHC and CHOL. The COAD box plot shows higher MLLT10 RNA expression in tumor versus normal tissue (log2 FC = +0.439, t-test p < 0.001).
This table shows molecular features associated with MLLT10 in patient tissues and cancer cell lines. In patient samples, MLLT10 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, MLLT10 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
